Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. Over the past five years, its total returns (which include dividend income) of 191% have eclipsed the S&P 500, which has increased by 113% when factoring in its distributions.
But there have been question marks about the future of AbbVie, especially with the company losing patent protection for its top-selling drug, Humira, next year. However, it has made moves, such as the acquisition of Botox-maker Allergan in 2020, to help diversify and grow its business. Should investors be worried about the stock, or is AbbVie likely to continue outperforming the market?
Image source: Getty Images.
Source Fool.com